Which Patients Qualify?
There are four different studies being conducted.

Gemini I and Gemini II (RMS)
Active control studies comparing tolebrutinib, the investigational study drug, to Aubagio® (teriflunomide) in patients with relapsing forms of multiple sclerosis (RMS). Testing the effect of the investigational drug on annualized relapse rate, disability progression, magnetic resonance imaging (MRI) lesions, the ability to learn and process information, and quality of life.
Key Inclusion
- Patients with Relapsing Multiple Sclerosis (RMS)
- Ages 18 to 55 years
- EDSS ≤ 5.5
Key exclusion criteria:
- Washout is required for patients currently taking ocrelizumab, teriflunomide, natalizumab, alemtuzumab, anticoagulants /antiplatelets (different washout periods are required for the DMTs).
- Patients diagnosed with cancer in the past 5 years, HIV, Hepatitis B or C, or class 3 or 4 heart failure, active/latent TB
- Patients hospitalized for any psychiatric condition in past 2 years
- Pregnant women or women planning to become pregnant in few years

Hercules (nrSPMS)
Placebo-control study comparing tolebrutinib, the investigational study drug, to placebo in patients with non-relapsing secondary progressive multiple sclerosis (nrSPMS). Testing the effect of the investigational drug on disability progression, magnetic resonance imaging (MRI) lesions, the ability to learn and process information, and quality of life.
Key Inclusion
- Patients with Non-Relapsing Secondary Progressive Multiple Sclerosis (nrSPMS)
- Ages 18 to 60 years
- No relapses in past 24 months
- EDSS of 2 to 6.5
Key Exclusion criteria:
- Washout is required for patients currently taking ocrelizumab, teriflunomide, natalizumab, alemtuzumab, anticoagulants/antiplatelets (different washout periods are required for the DMTs).
- Patients diagnosed with cancer in the past 5 years, HIV, Hepatitis B or C, or class 3 or 4 heart failure, active/latent TB
- Patients hospitalized for any psychiatric condition in the past 2 years
- Pregnant women or women planning to become pregnant in the next 4 years

Perseus (PPMS)
Placebo-control study comparing tolebrutinib, the investigational study drug, to placebo in patients with primary progressive multiple sclerosis (PPMS). Testing the effect of the investigational drug on disability progression, magnetic resonance imaging (MRI) lesions, the ability to learn and process information, and quality of life.
Key Inclusion:
- Patients with Primary Progressive Multiple Sclerosis (PPMS)
- Ages 18 to 55 years
- EDSS of 2 to 6.5
Key Exclusion criteria:
- Washout is required for patients currently taking ocrelizumab, teriflunomide, natalizumab, alemtuzumab, anticoagulants/antiplatelets (different washout periods are required for the DMTs).
- Patients diagnosed with cancer in the past 5 years, HIV, Hepatitis B or C, or class 3 or 4 heart failure, acute/latent tuberculosis (TB)
- Patients hospitalized for any psychiatric condition in the past 2 years
- Pregnant women or women planning to become pregnant in the next 4 years